Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio's OXL001 Development Program

NOTTINGHAM, England, Sept. 29, 2022 /PRNewswire/ -- Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences

Related Keywords

United Kingdom ,Nottingham ,Prnewswire Oxilio ,Trx Biosciences ,Kostenloser Wertpapierhandel ,Mark Egerton ,Simon Yaxley ,Research Ethics Committee ,Quotient Sciences Translational Pharmaceutics ,Quotient Sciences ,Regulatory Agency ,United Kingdom Medicines ,Clinical Trial Application ,Quotient Science ,Translational Pharmaceutics ,Oxilio ,Quotient ,Ciences ,Nnounce ,Egulatory ,Approval ,Xl001 ,Development ,Program ,